May Measurement Month 2018: an analysis of blood pressure screening results from United Arab Emirates

Afzalhussein Yusufali1,2,*, Nooshin Bazargani3, Buthaina A. Bin Belaila4, Aisha M. Suhail4, Hassan H. Shuri5, Amrish Agrawal6, Khalifa Muhammed7, Ahmed Gabroun8, Amer Albawab1, Zainab Vazir7, Rajakumari Ravi Kumar1, Dana Ghannam9, Thomas Beaney10,11, Anca Chis Ster10, and Neil R. Poulter10

1Dubai Health Authority, Hatta Hospital, Dubai, UAE; 2Dubai Medical University, Dubai, UAE; 3Dubai Hospital, Dubai Health Authority, Dubai, UAE; 4UAE Ministry of Health and Prevention; 5Medical Fitness Services, DHA, Dubai, UAE; 6Ministry of Health and Prevention, Fujairah Hospital, Fujairah, UAE; 7Rashid Hospital, Dubai Health Authority, Dubai, UAE; 8United Medical Center, Dubai, UAE; 9Dubai Medical University, Dubai, UAE; 10Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London, W12 7RH, UK; and 11Department of Primary Care and Public Health, Imperial College London, London, W6 8RP, St, Dunstan’s Road UK

KEYWORDS
Hypertension; Blood pressure; Screening; Treatment; Control; UAE

Hypertension is one of the most important modifiable risk factors for cardiovascular disease and death even in high-income countries. According to the PURE Study, globally only half of hypertensives are aware and less than a fifth controlled. May Measurement Month (MMM) is a global campaign to raise awareness and screen for high blood pressure (BP) in lieu of formal screening. United Arab Emirates (UAE) has taken part in MMM since its inception and here data from MMM18 are reported. Trained volunteers from 54 sites screened 31 316 individuals from all the Emirates of UAE using convenience sampling. Blood pressure measurement, the definition of hypertension, and statistical analysis followed the standard MMM protocol. The mean age was 36.8 ± 11.4 years and 18 411 (59%) were male. Participants of Arab descent were 11 829 (38%) and 11 569 (37%) were South Asian. Mean body mass index was 26.8 ± 5.29 kg/m². Of those screened, 7 917 (25%) had never had a BP recorded, while 16 892 (54%) had recorded BP in the previous year. After imputation, 6 243 (20%) had hypertension. Of those participants, only 2 540 (41%) were aware and 2 331 (37%) were on antihypertensive medication, of which 61% were controlled. Of all hypertensives, only 23% were controlled. May Measurement Month in UAE expanded significantly compared to 2017. A quarter had never had BP measured and awareness of hypertension low (41%). This opportunistic screening method found a substantial number of adults with untreated or inadequately treated hypertension.

*Corresponding author. Tel: +971 04 2191936; +971 55 404 6993, Fax: +971 4 3113113, Email: ahyusufali@dha.gov.ae

Published on behalf of the European Society of Cardiology. © The Author(s) 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

Cardiovascular disease (CVD) continues to be the leading cause of death in the United Arab Emirates (UAE). Hypertension remains one of the most important modifiable risk factors for CVD and mortality worldwide, even in high-income countries. Worldwide, more than half of those with hypertension are unaware. In the UAE, the age and sex standardized hypertension prevalence is estimated at 33%, while awareness has been recorded at 49%, treatment 47%, and control only 19%. Screening for CVD risk factors has been a national priority. May Measurement Month (MMM) is the largest worldwide synchronized awareness and screening project in lieu of a systematic screening program. The UAE took part in 2017, and the results suggested that opportunistic screening could identify significant numbers with raised BP. We report the results of MMM18 from the UAE.

Methods

The MMM18 protocol was similar to MMM17 with minor changes. New variables measured were awareness and screening site type. Ethical approval (DSREC-03/2018-6) was from Dubai Health Authority's Dubai Scientific Research Ethical Committee. The UAE Ministry of Health and Prevention (MOHAP), Dubai Health Authority (DHA), and Dubai Medical University and Pharmacies took part in MMM18 for the whole of the month of May 2018. There were 54 centres manned by 245 volunteers consisting of layperson, health workers, nurses, medical students, and physicians. Convenient sites were chosen in order to get the greatest number of adults above 18 years of age, who ideally had not had a blood pressure (BP) measurement in the past year. It varied from homes, workplaces, markets, pharmacy to clinic, and hospital foyers. The volunteer staff were trained on the background and the objectives of MMM, the one-page questionnaire, and the different methods of capturing data via an MMM18 App, on a case report form or on dedicated excel sheet was practiced. A standardized method of BP measurement using either an automated or a manual sphygmomanometer was encouraged using BP measurement video from the MMM website and face to face on-site training. Three sitting measurements within a minute of each other, after 5 min of rest was required.

Availability of free BP measurement was advertised at the designated sites using prior announcement, posters, and pull-down banners. Volunteers for screening were self-invited. Heights and weights were also measured where possible, otherwise they were estimated by screeners.

There was no direct source of funding. However, we received help in kind from the UAE Ministry of Health and Prevention (MOHAP), Dubai Health Authority (DHA), public and private hospitals/clinics and from Les Laboratoires Servier. We received Omron BP devices from Omron Healthcare Co. Ltd.

Definition of hypertension diagnosis, awareness, treatment, and control are as published in the MMM18 global paper. Briefly, hypertension was defined as those with a systolic BP of ≥140 mmHg or a diastolic BP of ≥90 mmHg on the basis of the mean of the second and third BP recording. Those taking antihypertensive medications were assumed to have hypertension and to be aware of their condition. Among those on treatment, controlled BP was defined as a systolic BP of <140 mmHg and a diastolic BP <90 mmHg. All data were sent directly via the App or cleaned and sent via Excel sheets. Data were analysed centrally by the MMM project team and multiple imputations performed based on the global data to impute the mean of readings 2 and 3 where this was missing. The age and sex standardized hypertension rate was calculated using the WHO world standard population.

Results

We screened 31,316 subjects from all seven Emirates in the UAE. The mean age was 36.8±11.4 years, 63% being below 40 years of age, and 18,411 (59%) male. Participants of Arab descent were 11,829 (38%) and 11,569 (37%) were South Asian. The screening sites were located in hospital or clinic areas in 21,678 (69%), public areas (indoors and outdoors) in 4795 (15%), and 2,918 (9%) in workplaces.

Only 3,046 (10%) had participated in MMM17, 7,917 (25%) had never had BP recorded in the past, while 16,892 (54%) had recorded a BP in the previous year. Antihypertensive treatment was being taken by 2,331 (7%), 2,561 (8%) reported diabetes, 252 (1%) had previous myocardial infarction and 177 (1%) previous history of stroke. A current pregnancy was reported by 720 (6%) of the women, and 7,328 (23%) were fasting as the campaign was conducted partially during the month of Ramadan.

Current smokers were 3,128 (10%) and alcohol use was reported in 2,535 (8%). Mean body mass index (BMI) was 26.8 (SD 5.2) kg/m² with 14,719 (47%) overweight or obese participants.

Three BP measurements were taken in 18,104 (58%). The number with raised BP from these was 5,333 (30%) using the first reading, 4,469 (25%) using the second reading and 4,071 (23%) using the third reading. On the other hand, the number with raised BP was 4,736 (26%) using the mean of 1st and 2nd reading, 4,134 (23%) using 2nd and 3rd reading, and 4,312 (24%) using all three readings.

After imputation and using the mean of 2nd and 3rd reading, 6,243 (20%) were found to have hypertension, of which 2,540 (41%) were aware of their high BP, 2,329 (37%) were on antihypertensive medication and only 22% were controlled. Of those on antihypertensive treatment, the control rate was 61% (Supplementary material online, Table S1). The number of newly detected hypertensives was 3,912. The age and sex standardized rate of hypertension was 25%.

Based on linear regression models and after adjusting for age and sex (with an interaction) and antihypertensive treatment, both systolic and diastolic BP were higher in smokers vs. non-smokers and dose-dependent alcohol consumption vs. non-consumers, while it was significantly lower in those fasting vs. non-fasting and amongst women who were pregnant vs. non-pregnant (Supplementary material online, F1). Participants who were overweight or...
obese were strongly associated with higher systolic and dia-
stolic measurements than participants who were of a
healthy weight. Conversely, underweight vs. healthy
weight participants were strongly associated with lower
systolic and diastolic BPs (Supplementary material online,
F2). There was a strong linear relationship between systolic
and diastolic BP and increasing BMI.

Compared to clinic or hospital-based measurements,
both BPs were significantly higher in indoor and outdoor
public areas as well as in the workplace (Supplementary
material online, F3). Similarly, both BPs were significantly
higher on Friday and Saturday compared to Mondays
(Supplementary material online, F4).

Discussion

Compared to 6 193 screened in MMM17, we were able to
screen five times more (31 316) during MMM18. This was
possible because of the involvement of larger numbers of
the relevant stakeholders. Action from such institutions as
awareness within the public is one of the key goals
of MMM.

For a quarter of those screened, this was their first ever
opportunity. This large gap in our screening system needs
addressing.

The association of high BP with smoking, alcohol, and
BMI was similar to that found in the global analysis, as was
the lower BP with pregnancy.6 We also found higher BP dur-
during our weekend (Friday and Saturday).7

Limitations are mentioned in the global paper.7 In brief,
this pertains to making an assumption of diagnosis using
three BP measurements in one sitting, using different BP
machines in different surroundings and the fact that
this was a self-selected and opportunistic convenience
sampling.

Conclusion

MMM18 showed that a large number of untreated and inad-
equately treated hypertension could be found by this op-
portunistic, volunteer-based screening. For 1 in 4, this was
their first BP measurement, and among the hypertensives,
only 4 in 10 were aware of their high BP. The increased
number of self-invited participants and the greater in-
volvement from the different stakeholders compared to
the previous year shows that MMM is perceived to be useful.
We plan to continue with MMM until this need is adequately
addressed.

Supplementary material

Supplementary material is available at European Heart
Journal Supplements online.

Acknowledgements

The authors thank the UAE Ministry of Health and
Prevention, Dubai Health Authority, Medical Fitness
Services, Dubai Medical University, United Medical Center,
Les Laboratoires Servier, Omron Healthcare Co., Ltd., all
local investigators, volunteers, and organizations.

Conflict of interest: none declared.

References

1. Dagenais GR, Leong DP, Rangarajan S, Larsson L, Muntner P,
Gupta R, Diao R, Avezum A, Oliveira GFB, Wielgosz A, Parambath S,
Mony P, Alhabib KF, Temizhan A, Ismail N, Chifamba J, Yeates K,
Khatib R, Rahman O, Zatonska K, Kazmi K, Wei L, Zhu J, Rosengren A,
Vijayakumar K, Kaur M, Mohan V, Yusufali A, Kelishadi R, Too K,
Joseph P, Yusuf S. Variations in common diseases, hospital admissions,
and deaths in middle-aged adults in 21 countries from five continents
(PURE): a prospective cohort study. Lancet 2020;395:785-794.
2. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M,
Kutty VR, Gupta R, Wielgosz A, Alhabib KF, Dans A, Lopez-Jaramillo P,
Avezum A, Larsson L, Abu-Auf M, Kruger R, Leong D, O’Donnell M, McKeever P,
Dagens G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individu-
als from 21 high-income, middle-income, and low-income countries
(PURE): a prospective cohort study. Lancet 2020;395:795-808.
3. Yusufali AM, Khatib R, Islam S, Alhabib KF, Bahonar A, Swidan HM,
Chifamba J, Yeates K, Kelishadi R, Yusufali K, Khatib R, Rahman O,
Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA,
Teo KK, Leong D, O’Donnell M, McKeever P, Dagens G. Noncommunicable
diseases, awareness, treatment and control of hypertension in four Middle East
countries. J Hypertens 2017;35:1457-1464.
4. National Plan for the Prevention and Control of Non-communicable
Diseases. Arab United Emirates Ministry of Health and Prevention. 2017.
5. Yusufali A, Bazargani N, Agraval A, Muhammed K, Obaid H, Gabrown
A, Albadwawi M, Albawab A, Musa A, Alraeesi F, Vazir Z, Varghese R,
Ravi Kumar R, Kobieissi E, Beaney T, Poulter NR. May Measurement
Month 2017: an analysis of blood pressure screening results from the
Arab United Emirates—Northern Africa and Middle East. Eur Heart J
Suppl 2019;21(Supplement D):D118-D120.
6. Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A,
Kruger R, Nilsson PM, Prabhakaran D, Ramirez AJ, Schlaich MP,
Schute AE, Tomaszewski M, Touyz R, Wang J-G, Weber MA, Poulter NR,
Burazeri G, Gjirjako G, Rishi E, Cunashi R, Fernandez MJCC,
Vicetoria Pereira SS, Neto MFMP, Oliveira PNM, Feijao ACG, Cemeliero Y,
Marin MJ, Garcia Vasquez F, Espege W, Stimson D, Fuentes IA,
Zilberman JM, Rodrigue P, Babinyan KY, Engibaryan AH, Avagyan AM,
Minasyan AA, Gevorkyan AT, Carnagiar R, Carrington MJ, Sharman JE,
Lee R, Peri S, Nieder E, Malik F-T-TN, Choudhury SR, Al Mamun MA,
Ishraquzzaman M, Anthony F, Connell K, De Backer TLM, Krzesinski J,
Houenouss MD, Houenanou CY, Sokolovic S, Bathtajirevic R, Tiro MB,
Mosepele M, Masupe TK, Barosso WS, Gomes MAM, Fettosa ADM,
Brandao AA, Miranda RD, Azvedo VMA, Dias LM, Garcia GDM,
Mattos IP, Dzudie A, Kingue S, Djoumou FAH, Njome E, Khan N, Lasan
FT, Garcia MS, Paccot MF, Torres Pi, Li Y, Liu M, Xu L, Li L, Chen X,
Deng J, Zhao W, Fu L, Zhou Y, Lopez-Jaramillo P, Otero J, Camacho
PA, Accini JL, Sanchez G, Arcos E, M’Buyama-Kabangou J-R, Katamba
PK, Ngoyo GN, Buila NM, Bayaua PM, Elienga Abolla BF, Bakekolo PR,
Kousala Landa CM, Kimbally Kaky GS, Kramoh EK, Gornon YNK, Olsen
AH, Valdez Valoy L, Santillan M, Angel Rafael GM, Peinaherrera CE,
Villaibal J, Ramirez AR, Arteaga F, Delgado P, Beistline H, Cappuccio FP,
Keitley J, Taylor T, Gusho DY, Kassie DM, Gebra SA, Pathak A, Denolle
T, Tsiaoamgvrishvilii B, Trapadize D, Sturban L, Abesadze T, Gridzelidze
N, Grabfelder M, Kramer BK, Schneider RE, Twumasi-Ankrah B,
Tannor EK, Lincoln MD, Deku EM, Wyss Quintana FS, Kensoner J, Jean
Baptiste ED, Saintilmond WW, Barrientos AL, Peiger B, Lagos AR,
Forgas MA, Lee WY, Tomlinson BW, Jarai Z, Pal G, More A, Maheshwari A,
Verma N, Sharma M, Mukherjee TK, Pattil M, Pulikottil Josef A, More A,
Takalikar A, Turana Y, Widyanbanto B, Danny SS, Djon
S, Handari SD, Tambunan M, Tiksna BB, Hermiawaty E, Tavassoli E,
Zolfaghari M, Dolan E, O’Brien E, Borghi C, Ferri C, Tortosa C, Parati
G, Nwokochara CR, Nwokochara M, Ogna EO, Gilton BM, Barasa AL,
Barasa FA, Wairague AW, Almaza M, Hajesm RN, Fageh HA,
Musalam OM, Derbi HA, Bettmara KA, Zakyasjekine U, Vickiene A,
Calmes J, Alkerwi A, Gantenbein M, Ndlovu HLL, Mowed G, Chirwa ML,
Nyrenda NM, Dhimani TD, Chia YC, Ching SM, Devaraj NK, Ouane
N, Fane T, Kowlessur S, Ori B, Heccharan J, Alcocer L, Chavez A, Ruiz
G, Espinosa C, Gomez-Alvarez E, Neupane D, Bhattarai H, Ranabhat
A, Yusufali et al. (H130)

Downloaded from https://academic.oup.com/europeanheartjournal-supple/article/22/Supplement_H/H128/5898723 by guest on 02 September 2020
K, Adhikari TB, Keirala S, Toure IA, Soumana KH, Wahab KW, Omotoso AB, Sani MU, Okubadejo NU, Nadar SK, Al-Riyami HA, Ishaq M, Memon F, Sidique S, Choudhry HA, Khan RA, Ayala M, Maidana AJO, Bogado GGG, Ona DI, Attilano A, Granada C, Bartolome R, Manese L, Mina A, Dumlao MC, Villaruel MC, Gomez L, Jóźwiak J, Malyszko J, Banach M, Mastej M, de Carvalho Rodrigues MM, Martins LL, Paval A, Dorobantu M, Konradi AO, Chazova IE, Rotar O, Spoares MC, Viegas D, Almustafa BA, Alshurafa SA, Brady A, Bovet P, Viswanathan B, Oladapo OO, Russell JW, Bruguljan-Hiti J, Bozic N, Knez J, Dolenc P, Hassan MM, Woodiwiss AJ, Myburgh C, Vally M, Ruijope LM, Molinero A, Rodilla E, Gijón-Conde T, Beheiry HM, Ali IA, Osman AAA, Fahal NAW, Osman HA, Altahir F, Persson M, Wuerzner G, Burkard T, Wang T-D, Lin H-J, Pan H-Y, Chen W-J, Lin E, Mondo CK, Ingabire PM, Khomazyuk TT, Krotova VV-Y, Negresku E, Evstigneeva O, Bazargani NN, Agrawal A, Bin Belaila BA, Suhail AM, Muhammed KO, Shuri HH, Wainford RD, Levy PD, Boggia JJ, Garré LL, Hernandez-Hernandez R, Octavio-Seijas JA, Lopez-Rivera JA, Morr I, Duin A, Huynh MV, Cao ST, Nguyen VL, To M, Phan HN, Cockcroft J, McDonnell B, Goma FM, Syatalimi C, Chifamba J, Gwini R, Tliburcio OV, Xia X; MMM Investigators. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J 2019;40:2006–2017.

7. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Ismail NH, Puaane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S; PURE (Prospective Urban Rural Epidemiology) Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959-968.